The Series B round of financing announced Thursday was led by venBio Partners. It comes as Camarillo, California-based ImmPACT reports encouraging early clinical data indicating how its treatment, ...
RICHMOND, Calif.--(BUSINESS WIRE)--Accurus Biosciences Inc. (“Accurus”) is pleased to announce that it has entered into a worldwide licensing agreement for its CLDN18.2 monoclonal antibody with ...
Two years ago, the fast-growing city of Austin had a dueling bulldozer issue. It responded to the issue with its own mapping application -- a Web-based GIS tool to help project managers, city ...
LOS ANGELES, Sept. 17, 2024 /PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies ...
Strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate Data from ImmPACT’s multi-center Phase 1-2 clinical trial of IMPT-314 in ...
—Senior healthcare executive with three decades' global experience across large pharma and diverse start-up organizations in finance and business development— WEST HILLS, Calif., Aug. 9, 2022 ...
Immpact Bio USA Inc. has obtained IND clearance from the FDA for IMPT-514, a CD19/CD20 bispecific chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with multiple ...
Phase 1/2 clinical trial expected to launch in early 2023 and will evaluate safety and preliminary impact on disease activity of IMPT-314 WEST HILLS, Calif., Jan. 24, 2023 /PRNewswire/ -- ImmPACT Bio ...
Lyell Immunopharma (LYEL) announced that it has entered into a definitive agreement to acquire ImmPACT Bio, a privately-owned clinical-stage biotechnology company. ImmPACT’s lead program, IMPT-314, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results